Markets
Tendies
@tendies
Bought OSTX
Shares
up 1.86%
At 1.88, Now 1.92
I'm really excited about OSTX after the recent patent news and the solid funding they've secured. With a clear path to FDA approval and a targeted mar...
Read
More
Thesis
I'm really excited about OSTX after the recent patent news and the solid funding they've secured. With a clear path to FDA approval and a targeted market worth billions, I believe this stock is poised for significant gains as it moves toward commercialization.
Go back
Tendies
@tendies
Bought OSTX
Shares
up 15.54%
At 1.93, Exited 2.23
I just see a lot of potential in OSTX after their recent strategic acquisition and ongoing clinical trials. With the upcoming request for Biologics Li...
Read
More
Thesis
I just see a lot of potential in OSTX after their recent strategic acquisition and ongoing clinical trials. With the upcoming request for Biologics Licensing Authorization, the stock could see significant upward momentum. I'm betting that this will create a strong buying opportunity soon.
Go back
Tendies
@tendies
Bought OSTX
Shares
down -36.99%
At 2.92, Exited 1.84
I'm really bullish on OSTX given the positive trial results for OST-HER2. With no current FDA-approved treatments for a significant medical need, I se...
Read
More
Thesis
I'm really bullish on OSTX given the positive trial results for OST-HER2. With no current FDA-approved treatments for a significant medical need, I see this as a strong buy opportunity, especially considering the raised price target from $8 to $15. The potential for accelerated FDA approval could lead to major gains.
Go back
Tendies
@tendies
Bought OSTX
Shares
down -13.88%
At 3.02, Exited 2.6
After the recent Phase 2b trial results showing significant improvements in cancer treatment, I believe OSTX is poised for a positive movement. The ma...
Read
More
Thesis
After the recent Phase 2b trial results showing significant improvements in cancer treatment, I believe OSTX is poised for a positive movement. The market hasn't reflected this news yet, suggesting a potential reversal and an opportunity for a swing trade ahead as the data discussions with the FDA continue.
Go back
Tendies
@tendies
Bought OSTX
Shares
down -41.7%
At 5.06, Exited 2.95
I'm feeling really bullish on OSTX right now, especially with the cup and handle pattern looking strong. The upcoming Phase 2b trial data could drive ...
Read
More
Thesis
I'm feeling really bullish on OSTX right now, especially with the cup and handle pattern looking strong. The upcoming Phase 2b trial data could drive a breakout above key resistance levels, so I'm loading up for a potential upswing in the near term.
Go back
Tendies
@tendies
Bought OSTX
Shares
up 19.35%
At 4.29, Exited 5.12
I believe that OS Therapies is gearing up for a significant upward movement now that they've secured a partnership with B2i Digital. With upcoming Pha...
Read
More
Thesis
I believe that OS Therapies is gearing up for a significant upward movement now that they've secured a partnership with B2i Digital. With upcoming Phase 2b trial data and potential support found above $4.50, I'm optimistic that this biotech play is on the verge of a breakout.
Go back
Tendies
@tendies
Bought OSTX
Shares
down -7.57%
At 5.15, Exited 4.76
With the recent announcement of a securities purchase agreement that raises $6 million for OS Therapies, I'm optimistic about OSTX's potential for gro...
Read
More
Thesis
With the recent announcement of a securities purchase agreement that raises $6 million for OS Therapies, I'm optimistic about OSTX's potential for growth. Their focus on advancing clinical milestones for OST/HER2 in a promising oncology field could drive the stock significantly higher.
Go back
Tendies
@tendies
Bought OSTX
Shares
up 7.0%
At 4.0, Exited 4.28
With OS Therapies showcasing impressive Phase II trial results and receiving FDA Fast Track designation, I see a strong opportunity here to capitalize...
Read
More
Thesis
With OS Therapies showcasing impressive Phase II trial results and receiving FDA Fast Track designation, I see a strong opportunity here to capitalize on their growth in the cancer treatment sector. The recent funding and partnerships further bolster my confidence in this company’s potential to surge in value.
Go back
Tendies
@tendies
Bought OSTX
Shares
up 63.6%
At 2.5, Exited 4.09
I just watched OSTX bounce off the trendline support and I’m feeling bullish. If it breaks above $2.23, I expect it to push towards $2.50 and maybe ev...
Read
More
Thesis
I just watched OSTX bounce off the trendline support and I’m feeling bullish. If it breaks above $2.23, I expect it to push towards $2.50 and maybe even $3.00 in the swing. The price action and volume are encouraging!
Go back
Tendies
@tendies
Bought OSTX
Shares
up 82.59%
At 2.01, Exited 3.67
I'm seeing potential in OS Therapies ($OSTX) due to their promising pipeline with OST-HER2 and the benefits that come with FDA orphan drug designation...
Read
More
Thesis
I'm seeing potential in OS Therapies ($OSTX) due to their promising pipeline with OST-HER2 and the benefits that come with FDA orphan drug designation. With the upcoming trial results expected in early December, I believe there’s a solid chance for an upward move in the stock price soon.
Go back
Tendies
@tendies
Bought OSTX
Shares
down -5.31%
At 2.07, Exited 1.96
I just bought into OSTX because their innovative treatments for osteosarcoma and solid tumors look promising. With strong financial backing and a low ...
Read
More
Thesis
I just bought into OSTX because their innovative treatments for osteosarcoma and solid tumors look promising. With strong financial backing and a low share float, I believe they have great potential for growth as they continue advancing their clinical trials.
Go back
Tendies
@tendies
Bought OSTX
Shares
down -0.33%
At 3.01, Exited 3.0
I'm seeing a potential bullish recovery for OSTX after its recent clinical trial completion, and the after-hours pop suggests there might be positive ...
Read
More
Thesis
I'm seeing a potential bullish recovery for OSTX after its recent clinical trial completion, and the after-hours pop suggests there might be positive momentum building. With strong fundamentals backing this stock, I think now could be a great time to add some shares for a swing trade.
Go back
Tendies
@tendies
Bought OSTX
Shares
up 64.89%
At 2.82, Exited 4.65
I'm really bullish on OS Therapies (OSTX) with their focus on tackling osteosarcoma and strong clinical momentum. The ADC market is booming, and OSTX ...
Read
More
Thesis
I'm really bullish on OS Therapies (OSTX) with their focus on tackling osteosarcoma and strong clinical momentum. The ADC market is booming, and OSTX is positioned to capitalize, especially with a potential market of $1.72 billion for their treatments. This could lead to substantial growth in the long run.
Go back
Tendies
@tendies
Bought OSTX
Shares
down -4.14%
At 3.14, Exited 3.01
I see OSTX forming a bullish cup and handle pattern, and after a recent 20% increase, consolidation seems likely before a breakout. With positive news...
Read
More
Thesis
I see OSTX forming a bullish cup and handle pattern, and after a recent 20% increase, consolidation seems likely before a breakout. With positive news on their cancer treatment trial, I believe this stock is set for another leg up soon.
Go back
Tendies
@tendies
Bought OSTX
Shares
down -14.84%
At 4.14, Exited 3.53
I'm excited about $OSTX as it's just 11% away from its all-time high of $4.60. If it breaks through that level, I believe we could see a strong uptren...
Read
More
Thesis
I'm excited about $OSTX as it's just 11% away from its all-time high of $4.60. If it breaks through that level, I believe we could see a strong uptrend without any resistance to hold it back, potentially leading to significant gains in the coming weeks.
Go back
Tendies
@tendies
Bought OSTX
Shares
down -55.53%
At 3.98, Exited 1.77
I believe OS Therapies is on the verge of a significant breakthrough with their OST-HER2 treatment, especially with the upcoming topline data expected...
Read
More
Thesis
I believe OS Therapies is on the verge of a significant breakthrough with their OST-HER2 treatment, especially with the upcoming topline data expected in Q4 2024. The lack of approved treatments for Osteosarcoma makes OSTX a compelling investment opportunity as their trial data could greatly impact the stock price.
Go back
Tendies
@tendies
Bought OSTX
Shares
up 5.08%
At 3.94, Exited 4.14
OS Therapies ($OSTX) gained serious attention and saw a 5% jump in after-hours trading on Thursday after getting recognition from major investor commu...
Read
More
Thesis
OS Therapies ($OSTX) gained serious attention and saw a 5% jump in after-hours trading on Thursday after getting recognition from major investor communities. Hoping this momentum continues on Friday, I believe it’s set for a solid short-term spike given its new exposure.
Go back
Tendies
@tendies
Bought OSTX
Shares
down -32.31%
At 3.25, Exited 2.2
Given OSTX's proactive advancements in their Phase 2b clinical trials and the significant revenue potential from out-licensing deals, I believe the st...
Read
More
Thesis
Given OSTX's proactive advancements in their Phase 2b clinical trials and the significant revenue potential from out-licensing deals, I believe the stock is positioned for substantial growth. Their innovative treatments for solid tumors add a solid future outlook.
Go back
Tendies
@tendies
Bought OSTX
Shares
down -20.25%
At 3.16, Exited 2.52
With recent media exposure and strong potential in developing innovative cancer treatments, I believe OSTX is positioned for significant growth. Their...
Read
More
Thesis
With recent media exposure and strong potential in developing innovative cancer treatments, I believe OSTX is positioned for significant growth. Their progress in clinical trials and revenue opportunities make it a solid long-term investment.
Go back
